Idecabtagen vicleucel (Abecma®) – Multiple myeloma (MM), at least 3 previous therapies

Characteristics

Start date 01.01.2022
Resolution 16.06.2022
INN Idecabtagen vicleucel
Brand name Abecma®
Pharm. company Bristol-Myers Squibb GmbH & Co KGaA
G-BA procedure ID 2022-01-01-D-779
Therapeutic area Oncological diseases ORPHAN
Reason for procedure Initial assessment
Regulatory status ATMP (CAR-T)

Indication (German)

Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

Subpopulation Indication Comparator
Adults with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies, including an immunomodulator, a proteasome inhibitor and an anti-CD38 antibody, and have shown disease progression on the last therapy. Not applicable

9. Associated procedures



<< List of all resolutions